Form 4: Cytek Director Michael Holder Acquires Shares via RSU Vesting

Cytek Biosciences Director Michael Holder acquired 2,181 shares of common stock through the exercise of Restricted Stock Units on November 18, 2025, increasing his direct beneficial ownership.

Summary

• Michael Holder, a Director of Cytek Biosciences, Inc. (CTKB), reported a change in beneficial ownership.
• On November 18, 2025, Holder acquired 2,181 shares of Cytek Biosciences common stock.
• This acquisition resulted from the exercise or conversion of derivative securities, specifically Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• Following this transaction, Holder directly beneficially owns 12,359 shares of common stock.
• Holder also directly beneficially owns 13,819 Restricted Stock Units.
• The RSU Award has a detailed vesting schedule, with portions vesting on August 18, 2024 (2/36), November 18, 2024 (3/36), March 10, 2025 (4/36), May 18, 2025 (2/36), and August 18, 2025 (3/36), and thereafter on those respective dates until fully vested.

Sentiment

Score: 6

Explanation: The transaction represents a routine vesting and acquisition of shares by a director, which can be viewed as a minor positive signal of continued alignment with shareholder interests, but is not a significant event.

Positives

• Director Michael Holder increased his direct beneficial ownership of common stock by 2,181 shares, aligning his interests further with shareholders.

Future Outlook

The remaining Restricted Stock Units held by Michael Holder are scheduled to vest according to a predetermined schedule, with portions vesting on various dates in 2024 and 2025 and thereafter.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, reflecting a director's compensation-related stock acquisition. It does not provide broader insights into industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The increase in a director's direct beneficial ownership of common stock may be perceived as a positive signal of management's confidence and alignment with shareholder value.

Next Steps

• Remaining Restricted Stock Units will vest according to the established schedule, with various portions vesting on August 18, 2024, November 18, 2024, March 10, 2025, May 18, 2025, and August 18, 2025, and thereafter.

Key Dates

Recommendation

This Form 4 reports a routine vesting and acquisition of shares by a director as part of their compensation plan. While it indicates continued alignment of interests, it does not present new information that would fundamentally alter the investment thesis for Cytek Biosciences, Inc. Therefore, a 'hold' recommendation is maintained, pending further operational or financial updates.

Keywords

Cytek Biosciences, CTKB, Form 4, insider transaction, stock acquisition, RSU, restricted stock units, director, beneficial ownership